Reducing prostaglandin E\textsubscript{2} production to raise cancer immunogenicity

Santiago Zelenay & Caetano Reis e Sousa

To cite this article: Santiago Zelenay & Caetano Reis e Sousa (2016) Reducing prostaglandin E\textsubscript{2} production to raise cancer immunogenicity, OncoImmunology, 5:5, e1123370, DOI: 10.1080/2162402X.2015.1123370

To link to this article: https://doi.org/10.1080/2162402X.2015.1123370

© 2016 The Author(s). Published with license by Taylor & Francis Group, LLC. Santiago Zelenay and Caetano Reis e Sousa.

Published online: 11 May 2016.

Submit your article to this journal

Article views: 1515

View related articles

View Crossmark data

Citing articles: 3 View citing articles
Reducing prostaglandin E2 production to raise cancer immunogenicity

Santiago Zelenaya and Caetano Reis e Sousab

aCancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK; bImmunobiology Laboratory, The Francis Crick Institute, Lincoln’s Inn Fields Laboratory, 44 Lincoln’s Inn Fields, London, UK

ABSTRACT
Cyclooxygenases (COX), commonly upregulated in numerous cancers, generate prostaglandin E2 (PGE2), which has been implicated in key aspects of malignant growth including proliferation, invasion and angiogenesis. Recently, we showed that production of PGE2 by cancer cells dominantly enables progressive tumor growth via immune escape and that cyclooxygenase inhibitors synergize with immunotherapy to enhance tumor eradication.

The remarkable recent success of certain type of immunotherapies such as those based on immune checkpoint blockade1 is testament to the notion that the immune system can act as a barrier to a wide range of malignancies. This has led, in turn, to a renewed interest in understanding the basis for cancer immune evasion. Identifying the mechanism/s underlying how cancer cells avoid immune control is fundamental for cancer treatment, especially as a marked fraction of patients fails to respond to immune-based therapies. In our recent study, “Cyclooxygenase-dependent tumor growth through evasion of immunity,”2 we demonstrate that COX-driven production of PGE2 by cancer cells enables immune escape and progressive tumor growth and show that this has therapeutic implications for cancer treatment.

Clinically apparent cancers are able to grow aggressively and invasively despite the presence of a seemingly functional immune system. The immunoediting theory posits that this characteristic is not due to an intrinsic inability of the immune system to detect oncogenically transformed cells but the result of a Darwinian process whereby the immune system selects for less immunogenic cancer cells.3 The immunogenic potential of tumor cells, as for any other entity, depends on antigen and adjuvant determinants.4 Low immunogenicity due to reduced antigenicity as a consequence of lack or loss of tumor antigens is a well-established mechanism of immunoediting.5-7 Adjuvanticity, that is, the ability of an antigenic stimulus to induce an immune response, has been less well studied in terms of cancer immunoediting. Adjuvant activity correlates with the ability to trigger innate immunity and induce activation of dendritic cells (DCs). Therefore, cancer cell traits that suppress or subvert DC activation are likely to contribute to decreased cancer immunogenicity and might constitute attractive therapeutic targets.

With this in mind, we set out to investigate the immunogenic properties of a cell line established from an autochthonous melanoma mouse model driven by the most common recurring mutation found in melanoma patients, a glutamic acid substitution for valine at position 600 of the B-RAF kinase (BrafV600E).8 We speculated that cancer cells isolated from a genetically engineered cancer-prone mouse with an intact immune system must have escaped immune surveillance and possess attributes that allowed them to avoid immune-mediated destruction. In agreement with our hypothesis, BrafV600E cells taken from cancer-bearing mice formed equally progressive tumors in T/B cell-sufficient or -deficient syngeneic mice underscoring their poor immunogenicity.

We went on to find that factors produced or released by BrafV600E cells had very potent immunomodulatory potential on mixed cultures of DCs and macrophages, which included the ability to directly induce the production of various tumor-promoting cytokines and chemokines such as IL-6, G-CSF or CXCL1. These effects could be attributed to PGE2 secretion by the melanoma cells following its synthesis through a canonical pathway dependent on the activity of COX and prostaglandin E synthases (PGES). Further in vitro and in vivo studies revealed that cancer cell-derived PGE2 was critical for the progressive growth of tumors formed by BrafV600E cells but also NrasG12D-driven melanoma, colorectal and breast cancer cell lines. Abrogation of the ability of cancer cells to produce PGE2 by means of genetic ablation of COX or PGES using CRISPR-Cas9 technology invariably and markedly impaired their potential for sustained growth in immunocompetent mice (Fig. 1). However, the COX- or PGES-deficient cells were able to grow in immunodeficient hosts indistinguishably from parental cells. This suggests that PGE2 production by tumor cells is primarily aimed at escaping adaptive immunity, which is unexpected given that it has been thought to be necessary for tumor cell proliferation, survival and angiogenesis.9 Finally, mice that rejected COX-deficient cancer cells were largely resistant to challenge with parental tumors indicating that PGE2 suppresses immunity rather than creating immune privilege.

CONTACT Santiago Zelenay Santiago.Zelenay@cruk.manchester.ac.uk; Caetano Reis e Sousa caetano@crick.ac.uk

Published with license by Taylor & Francis Group, LLC © Santiago Zelenay and Caetano Reis e Sousa.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
COX deficiency in cancer cells was associated with a marked shift in the inflammatory signature at the tumor site characterized by lower expression of cancer-promoting factors and concomitant increase in several mediators typically associated with antitumor immunity. The latter included increased accumulation of IL-12-producing Batf3-dependent CD103⁺ DCs providing further evidence that PGE₂ suppresses anticancer immunity (Fig. 1). Thus, a COX signature in tumor biopsies might constitute a biomarker of lessened immune control, which could perhaps be utilized to predict unresponsiveness to immunotherapy.

The drastic effects of genetically ablating PGE₂ production by tumors prompted us to assess whether pharmacological intervention might achieve similar results. Given the genetic evidence indicating the necessity of completely blocking PGE₂ synthesis before establishment of immune control could be observed, we did not expect COX inhibitors to be effective by themselves. However, even incomplete COX inhibition by drugs might be sufficient to potentiate immune-dependent control. Indeed, we found that giving mice COX-inhibitors, such as aspirin or celecoxib, together with anti-PD-1 blocking antibody synergistically promoted adaptive immune-mediated control of COX-competent cancers. These preclinical data suggest that COX-inhibitors could be useful to enhance the efficacy of anticancer immunotherapy. This prediction will now need to be tested in the context of a clinical trial and adds to the interest in assessing the efficacy of aspirin as a cancer chemopreventive agent.¹⁰

Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.

References
1. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015; 161:205-14; PMID:25860605; http://dx.doi.org/10.1016/j.cell.2015.03.030
2. Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, Quezada SA et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell 2015; 162(6):1257-70; PMID:26343581; http://dx.doi.org/10.1016/j.cell.2015.08.015
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486
4. Zelenay S, Reis e Sousa C. Adaptive immunity after cell death. Trends Immunol 2013; 34:329-35; PMID:23608152; http://dx.doi.org/10.1016/j.it.2013.03.005
5. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen Y-S, Shea LK et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482:400-4; PMID:22318521; http://dx.doi.org/10.1038/nature10755
6. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012; 482:405-9; PMID:22318517; http://dx.doi.org/10.1038/nature10803
7. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015; 160:48-61; PMID:25594174; http://dx.doi.org/10.1016/j.cell.2014.12.033
8. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R. Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice. Cancer Cell 2009; 15:294-303; PMID:19345328; http://dx.doi.org/10.1016/j.ccr.2009.02.022

9. Wang D, Dubois RN. Eicosanoids and cancer. Nature Rev Cancer 2010; 10:181-93; PMID:20168319; http://dx.doi.org/10.1038/nrc2809

10. http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2015-10-22-worlds-largest-clinical-trial-on-aspirin-to-stop-cancer-returning-launches-today